Latest news with #StacyKu
Business Insider
17-06-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and KalVista Pharmaceuticals (KALV)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immuneering (IMRX – Research Report) and KalVista Pharmaceuticals (KALV – Research Report) with bullish sentiments. Confident Investing Starts Here: KalVista Pharmaceuticals (KALV) In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on KalVista Pharmaceuticals, with a price target of $30.00. The company's shares closed last Monday at $13.04. According to Ku has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.9% and a 40.2% success rate. Ku covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Supernus Pharmaceuticals, and Verrica Pharmaceuticals. Currently, the analyst consensus on KalVista Pharmaceuticals is a Strong Buy with an average price target of $27.13, an 118.4% upside from current levels. In a report issued on June 13, Bank of America Securities also maintained a Buy rating on the stock with a $22.00 price target.
Business Insider
17-06-2025
- Business
- Business Insider
TD Cowen Remains a Buy on Supernus Pharmaceuticals (SUPN)
TD Cowen analyst Stacy Ku maintained a Buy rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price target of $45.00. The company's shares closed today at $32.47. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Ku covers the Healthcare sector, focusing on stocks such as LENZ Therapeutics, Supernus Pharmaceuticals, and scPharmaceuticals. According to TipRanks, Ku has an average return of -5.9% and a 40.23% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Supernus Pharmaceuticals with a $40.00 average price target.
